Roche/AbbVie Move Beyond GDC-0199 Toxicity Issue To Show Results In Tough-To-Treat CLL
This article was originally published in The Pink Sheet Daily
Small molecule Bcl-2 inhibitor GDC-0199/ABT-199 demonstrates an 84% overall response rate and a 23% complete response in early study of high risk CLL presented at ASH. However, tumor lysis syndrome caused one sudden death in the trial and is a potential risk that needs to be well-managed going forward. Roche also reports updated results of Gazyva vs. Rituxan in CLL.
You may also be interested in...
FDA denied breakthrough therapy request until AbbVie and Roche demonstrated substantial improvement over available treatment in 17p deletion chronic lymphocytic leukemia, review documents show.
Roche/Abbvie’s first-in-class breakthrough BCL-2 inhibitor granted accelerated approval by FDA in relapsed CLL with 17p deletion.
With new drugs at hand to protect its Herceptin breast cancer franchise, Roche announced positive data for its rituximab replacement candidate and other steps in its plan to protect top-seller Rituxan/MabThera.